Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

HOOKIPA Pharma Inc. HOOK OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
54/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$3.00
+167.9%

HOOKIPA Pharma Inc. (HOOK) is a Biotechnology company in the Healthcare sector, currently trading at $1.12. It has a SharesGrow Score of 54/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is HOOK = $3 (+167.9% upside).

Financials: revenue is $44M, +45.6%/yr average growth. Net income is $44M (loss), growing at +11.7%/yr. Net profit margin is -99% (negative). Gross margin is 100% (+25.2 pp trend).

Balance sheet: total debt is $875,000 against $51M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 3.27 (strong liquidity). Debt-to-assets is 1.1%. Total assets: $83M.

Analyst outlook: 5 / 9 analysts rate HOOK as buy (56%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 90/100 (Pass), Past 0/100 (Fail), Health 67/100 (Partial), Moat 50/100 (Partial), Future 64/100 (Pass), Income 10/100 (Fail).

$3.00
▲ 167.86% Upside
Average Price Target
The 12-month price target for HOOKIPA Pharma Inc. is $3.00.

HOOK SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 90/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 50/100
Gross margin is + market cap
FUTURE 64/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HOOK

✓
VALUE Pass
100/100
HOOK trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $3, implying +167.9% from the current price $1. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
90/100
HOOK: +45.6%/yr revenue is, +11.7%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet HOOK: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 3.27 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
50/100
HOOK: Gross margin is 100% (+25.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 50/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
64/100
Analyst outlook: 5 / 9 analysts rate HOOK as buy (56%). Analyst consensus target is $3 (+167.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
HOOK: Net profit margin is -99%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range0.721-1.77
Volume26.15K
Avg Volume (30D)10.89K
Market Cap$14.02M
Beta (1Y)0.77
Share Statistics
EPS (TTM)-3.47
Shares Outstanding$12.54M
IPO Date2019-04-18
Employees82
CEOMalte Peters
Financial Highlights & Ratios
Revenue (TTM)$43.95M
Gross Profit$43.95M
EBITDA$-40.85M
Net Income$-43.5M
Operating Income$-51.46M
Total Cash$39.68M
Total Debt$875K
Net Debt$-38.81M
Total Assets$82.55M
Price / Earnings (P/E)-0.3
Price / Sales (P/S)0.32
Analyst Forecast
1Y Price Target$3.00
Target High$3.00
Target Low$3.00
Upside+167.9%
Rating ConsensusBuy
Analysts Covering9
Buy 56% Hold 33% Sell 11%
Price Target Summary
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINUS43906K2096

Price Chart

Track all markets on TradingView
HOOK
HOOKIPA Pharma Inc. ↗  ·  Other OTC
Healthcare • Biotechnology
0.72 52WK RANGE 1.77

People Also View

TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 INZY
INZY
Inozyme Pharma, Inc.
$4.00
+0.25%
 ELDN
ELDN
Eledon Pharmaceuticals, Inc.
$3.20
-0.62%
 ABOS
ABOS
Acumen Pharmaceuticals, Inc.
$2.68
+6.77%
 PDSB
PDSB
PDS Biotechnology Corporation
$1.06
-2.75%
 MREO
MREO
Mereo BioPharma Group plc
$0.33
+2.81%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message